Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. (MRNA) appointed Juan Andres Chief Operating Officer, effective October 5, 2026. He will report to CEO Stéphane Bancel, serve on the Executive Committee and lead the manufacturing organization. Jerh Collins, Chief Technical Operations and Quality Officer, will retire.
Andres’s initial annual base salary is $800,000. He is eligible for an annual cash bonus, beginning with a prorated 2026 bonus, with a target equal to 90% of base salary; company and individual goals apply, with achievement determined at the Compensation Committee’s sole discretion. He is eligible for a $5 million new-hire equity award with four-year vesting, and no more than 75% of its value may be RSUs. Future annual equity awards have a target value of $4 million to $5 million, subject to committee approval and adjustment. Moderna said the appointment comes as it prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results.
Moderna, Inc. (MRNA) reported that President Stephen Hoge exercised stock options and sold a portion of the resulting shares under a pre‑arranged trading plan. On September 14 and 15, 2026 he exercised options for a total of 152,905 shares of common stock at an exercise price of $12.21 per share.
Across those two days, Hoge sold 80,575 shares of common stock in market transactions at weighted average prices of $144.13 and $146.07 per share, with actual sale prices ranging from $143.99 to $146.27. The plan was adopted on June 15, 2026 pursuant to Rule 10b5‑1. He also reports indirect holdings of 4,116 shares through Valhalla, LLC and 151,933 shares held by a family trust, for which he disclaims Section 16 beneficial ownership except for any pecuniary interest.
Moderna, Inc. (MRNA) reported that officer Stephen Hoge filed a notice under Rule 144 for a planned sale of 40,281 shares of common stock, expected on or after September 15, 2026, in connection with a stock option exercise, with Fidelity Brokerage Services LLC acting as broker.
The notice also lists Hoge’s prior Rule 144 sales of Moderna common stock over the past three months in three separate transactions.
Moderna, Inc. (MRNA) reported that Chief Financial Officer James M. Mock exercised options for 19,836 shares of common stock at an exercise price of $30.96 per share on September 10, 2026, and received the underlying shares.
On the same date, he sold 34,836 shares of common stock at $134.49 per share in market transactions, including the 19,836 shares from the option exercise and an additional 15,000 shares, pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. Following the exercise, he held 43,642 stock options expiring March 1, 2035.
Moderna, Inc. (MRNA) insider Stephen Hoge filed a Rule 144 notice planning to sell 40,294 shares of common stock, with an aggregate market value of $5,807,745.84, through Fidelity Brokerage Services LLC, with an expected sale date of September 14, 2026 on NASDAQ.
The planned sale is tied to a stock option exercise with cash payment to the issuer. Moderna reports 399,235,889 shares outstanding, which is a baseline figure, not the amount being sold. Hoge also sold 53,336 shares on June 15, 2026 for $2,739,870.32 and 53,336 shares on July 15, 2026 for $3,605,513.60.
Moderna, Inc. (MRNA) received a Rule 144 notice that officer James M. Mock, through Fidelity Brokerage Services LLC, plans to sell up to 34,836 shares of common stock, with an indicated aggregate market value of $4,685,093.64, beginning on or about September 10, 2026.
The shares derive from multiple restricted stock vesting events between October 5, 2023 and May 28, 2025 and a planned stock option exercise of 19,836 shares for cash on September 10, 2026. Common shares outstanding are stated as 399,235,889.
Moderna, Inc. (MRNA) reported that Chief Financial Officer James M. Mock exercised restricted stock units into common stock as part of a scheduled vesting. On September 4, 2026, 11,797 restricted stock units converted into 11,797 shares of common stock on a one-for-one basis, and 5,704 of those shares were withheld to satisfy tax withholding obligations. After the conversion, Mock held 106,179 restricted stock units directly, with future vesting occurring in equal quarterly installments as previously scheduled; no Rule 10b5-1 trading plan is reported.
Moderna, Inc. (MRNA) reported that Chief Legal Officer Shannon Thyme Klinger had restricted stock units vest on September 4, 2026, converting 11,797 RSUs into the same number of common shares on a one-for-one basis. Of these, 5,704 shares were withheld at $148.87 per share to satisfy tax withholding obligations, resulting in a net share delivery to her while 106,179 restricted stock units remain outstanding under this award schedule. No transactions were reported under a Rule 10b5-1 trading plan.
Moderna, Inc. (MRNA) reported that Chief Legal Officer Shannon Thyme Klinger exercised stock options and settled restricted stock units on September 1, 2026. She exercised 3,471 options at $30.96 per share into common stock and sold 3,471 shares at $139.95 per share under a Rule 10b5-1 trading plan adopted on September 9, 2025. In addition, 2,166 restricted stock units converted into common stock on a one-for-one basis, and 1,048 shares were withheld to satisfy tax withholding obligations in connection with RSU vesting. Following these transactions, she continued to hold 34,716 stock options and 21,661 restricted stock units directly.
Moderna, Inc. (MRNA) reported that Chief Financial Officer James M. Mock exercised restricted stock units on September 1, 2026, converting 2,475 restricted stock units into an equal number of shares of common stock on a one-for-one basis. In connection with this vesting, 1,197 common shares were withheld at a price of $140.34 per share to satisfy tax withholding obligations. Following this transaction, Mr. Mock continued to hold 24,755 restricted stock units subject to the award, which vested 25% on March 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter. No Rule 10b5-1 trading plan is reported for these transactions.